pain opportunity underappreciated. Acute pain trial result to be disclosed soon. The biotech developing a drug to treat acute pain that is not an opioid., a stock in the CNBC Investing Club portfolio, gets price target cut to $82 per share from $102 at Wells Fargo. Keeps equal weight rating.
price target to $55 per share from $60. The analysts' earnings estimates ahead of quarter are largely in-line with consensus.Jim's Charitable Trust31-year-old teacher quit her job. Now she works at Costco—and boosted her income by 50%: ‘I've never been happier'I left the U.S. for Denmark. Now I pay $2,100/month to live in this luxury apartment—and I'm much happier here
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: